Gene therapy for cancer: Regulatory considerations for approval

Cancer Gene Therapy

Volumn 22, Issue 12, 2015, Pages 554-563

  Husain, S R ^a   Han, J ^a   Au, P ^a   Shannon, K ^a   Puri, R K ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GENE THERAPY; CANCER PATIENT; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; PROOF OF CONCEPT; REVIEW; STUDY DESIGN; TOXICOLOGY; DRUG APPROVAL; GENE THERAPY; GENE VECTOR; GENETICS; LEGISLATION AND JURISPRUDENCE; NEOPLASMS; PATIENT SAFETY; STANDARDS; UNITED STATES;

DRUG APPROVAL; GENETIC THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS; PATIENT SAFETY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84947743247     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2015.58     Document Type: Review

References (46)

1. Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012 - an update. J Gene Med 2013; 15: 65-77.
2. Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 2002; 1: 347-355.
3. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
4. Rythe RCC, Flynt AS, Phillips JA III, Patton JG. siRNA therapeutics: big potential from small RNAs. Gene Ther 2005; 12: 5-11.
5. Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 2010; 9: 57-67.
6. Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 2013; 153: 910-918.
7. NIH Guideline for Research Involving Recombinant or Synthetic Nucleic Acid Molecules. Available at http://osp.od.nih.gov/office-biotechnology-activities/biosafety/nih-guidelines.
8. Ibraheem D, Elaissari A, Fessi H. Gene therapy and DNA delivery systems. Int J Pharm 2014; 459: 70-83.
9. Yang Y, Su Q, Wilson JM. Role of viral antigens in destructive cellular immune responses to adenovirus vector transduced cells in mouse lungs. J Virol 1996; 70: 7209-7212.
10. Hermonat PL, Quirk JG, Bishop BM, Han L. The packaging capacity of adenoassociated virus (AAV) and the potential for wild-type-plus AAV gene therapy vector. FEBS Lett 1997; 407: 78-84.
11. Samulski RJ, Zhu X, Xiao X, Brook JD, Housman DE, Epstein N et al. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J 1991; 10: 3941-3950.
12. Toussaint B, Chauchet X, Wang Y, Polac B, Le Gouellec A. Live-attenuated bacteria as a cancer vaccine vector. Exp Rev Vaccines 2013; 12: 1139-1145.
13. Gill DR, Southern KW, Mofford KA, Seddon T, Huang L, Sorgi F et al. A placebocontrolled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther 1997; 4: 199-209.
14. Konstan MW, Davis PB, Wagener JS, Hilliard KA, Stern R, Milgram LJ et al. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum Gene Ther 2004; 15: 1255-1269.
15. Niidome T, Huang L. Gene therapy progress and prospects: nonviral vectors. Gene Ther 2002; 9: 1647-1652.
16. Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology, June 2014. Available at www.fda.gov/RegulatoryInformation/Guidances/ucm257698.htm.
17. Guidance for FDA Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs), April 2008. Available at http://www.fda. gov/cber/guidelines.htm.
18. Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps), August 2007. Available at http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceCompliance RegulatoryInformation/Guidances/Tissue/UCM091345.pdf.
19. Point to Consider in the Characterization of Cell Lines Used to Produce Biologicals, July 1993. Available at http://www.fda.gov/cber/gdlns/ptccell.pdf.
20. ICH document Q5D: Derivation and Characterization of Cell Substrates Used for Production of Biotechnological/Biological Products (63 FR 50244, September 1998). Available at http://www.fda.gov/BiologicsBloodVaccines/GuidanceCom plianceRegulatoryInformation/Guidances/default.htm.
21. Guidance for Industry: cGMP for Phase 1 Investigational Drug, July 2008. Available at http://www.fda.gov/cber/guidelines.htm.
22. ICH Guidance on Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin, (63 FR 51074, 24 September 1998). Available at http://www.ich.org/products/guidelines/quality/quality-single/article/viralsafety- evaluation-of-biotechnology-products-derived-from-cell-lines-of-human-oranimal- origin.html.
23. ICH Topic Q3 Impurities. Guidance for Industry: Q3A Impurities in New Drug Substances, February 2003. Available at http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073385.pdf.
24. Guidance for Industry: Q3B (R2) Impurities in New Drug Products, July 2006. Available at http://www.fda.gov/downloads/drugs/guidancecomplianceregulatory information/guidances/ucm073389.pdf.
25. Guidance for Industry: Q3C Impurities: Residual Solvents, December 1997. Available at http://www.ich.org/products/guidelines/quality/quality-single/article/impurities-guideline-for-residual-solvents.html.
26. CFR: Code of Federal Regulations Title 21, 21 August 2015. Available at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=610.12.
27. United States Pharmacopoeia (USP), Chapter o714 Sterility Tests, 23rd edn, 1995. Available at http://www.usp.org.
28. Guidance for Industry: Q1A (R2): Stability Testing of New Drug Substances and Products (Revision 2), November 2003. Available at http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073369.pdf.
29. ICH Harmonized Tripartite Guidance Q1E: Evaluation of Stability Data, June, 2004. Available at http://www.ich.org/products/guidelines/quality/quality-single/article/evaluation-of-stability-data.html.
30. Guidance for Industry: Potency Tests for Cellular and Gene Therapy Products, January 2011. Available at http://www.fda.gov/BiologicsBloodVaccines/Guidance ComplianceRegulatoryInformation/Guidances/default.htm.
31. Draft Guidance for Industry: Comparability Protocol - Protein Drug Products and Biological Products-Chemistry, Manufacturing, and Controls Information, September 2003. Available at http://www.fda.gov/cber/guidelines.htm.
32. Simek SL. Characterization of gene therapy products and the impact of manufacturing changes on product comparability. Dev Biol (Basel) 2005; 122: 139-144.
33. International Conference on Harmonization: Guidance for Industry: Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process, June 2005. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073476.pdf.
34. Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products, November 2013. Available at http://www.fda.gov/Biologics BloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.
35. Guidance for Industry: Determining the Need for and Content of Environmental Assessments for Gene Therapies, Vectored Vaccines, and Related Recombinant Viral or Microbial Products, March 2015. Available at http://www.fda.gov/Biolo gicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Cellu larandGeneTherapy/ucm401869.htm.
36. Shenk-Braat EA, van Mierlo MM, Wagemaker G, Bangma CH, Kaptein LC. An inventory of shedding data from clinical gene therapy trials. J Gene Med 2007; 9: 910-921.
37. Brandon EF, Hermsen HP, van Eijkeren JC, Tiesjema B. Effect of administration route on the biodistribution and shedding of replication-deficient AAV2: a qualitative modeling approach. Curr Gene Ther 2010; 10: 91-106.
38. Guidance for Industry: Design and Analysis of Shedding Studies for Virus or Bacteria-Based Gene Therapy and Oncolytic Products, August 2015. Available at http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulator yInformation/Guidances/default.htm.
39. Guidance for Industry: Gene Therapy Clinical Trials-Observing Subjects for Delayed Adverse Events, November 2006, Available at http://www.fda.gov/biolo gicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/cellular andgenetherapy/ucm072957.htm.
40. Guidance for Industry: Preclinical Assessment of Investigational Cellular and Gene Therapy Products, November 2013. Available at http://www.fda.gov/Biologics BloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Cellularand GeneTherapy/ucm388218.htm.
41. Guidance for Industry: Clinical Considerations for Therapeutic Cancer Vaccines, October 2011. Available at http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/UCM278673.pdf.
42. Hacein-Bey-Abina S, von Kalle K, Schmidt M, Le Deist F, Wulffraat N, McIntyre E et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255-256.
43. Guidance for Industry: Supplemental Guidance on Testing for Replication Competent Retrovirus in Retroviral Vector Based Gene Therapy products and During Follow-up of Patients in Clinical Trials Using Retroviral Vectors, November 2006. Available at http://www.fda.gov/cber/guidelines.htm.
44. Miller DL, Ross JJ. Vaccine INDs: review of clinical holds. Vaccine 2005; 23: 1099-1101.
45. Takefman D, Bryan W. The state of gene therapies: the FDA perspective. Mol Therapy 2012; 20: 877-878.
46. CBER SOPP 8101.1, Scheduling and Conduct of Regulatory review Meetings with Sponsors and Applications, 15 October 2012. Available at http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Procedur esSOPPs/ucm079448.htm.